Abstract:Abstract Background and aims Chronically elevated levels of circulating lipoprotein-amyloid-beta (Abeta) are implicated in the disruption of the blood-brain barrier and the initiation of a neurodegenerative cascade leading to Alzheimers disease (AD). Type 2 diabetes is associated with BBB dysfunction, dyslipidaemia, and an increased risk of AD. However, alterations in triglyceride-rich lipoproteins (TRL)-Abeta homeostasis and its downstream effects on the BBB in a diabetes context remain explored. This study aimed to 1) investigate, in a preclinical model of diabetes, the hypothesis that diabetes-induced impairments in TRL-Abeta metabolism might compromise BBB integrity and exacerbate cognitive function and behavioural changes, and 2) assess the efficacy of interventions that improve TRL catabolism, including probucol, HA1, and ApoC3 siRNA, to prevent disease progression by lowering circulating TRL-Abeta levels. Methods Five-week-old db/db mice underwent a 9- or 23-weeks dietary interventions with probucol, a probucol prodrug HA1, or a standard diet with four-weekly injections of ApoC3 siRNA. Db/+ mice served as negative controls for each treatment duration. Blood levels of Abeta and ApoB were measured using ELISA. Immunofluorescence imaging was used to quantify enterocytic levels of Abeta and ApoB, and assess changes in neurovascular integrity (IgG, PDGFRbeta, ZO1, occludin), neuroinflammation (GFAP, Iba1), and cerebral oxidative stress (8OHdG). Results Our results indicate that diabetes increased the abundance of plasma amyloid, specifically Abeta42, which correlated with enterocytic abundance, suggesting exaggerated postprandial excretion. Disrupted plasma amyloid homeostasis was associated with BBB breakdown, including diminished barrier function, and the loss of pericytes and astrocytes. Provision of the probucol analogue, HA1, normalised plasma and enterocytic amyloidemia concomitant with the preservation of the neurovascular junction. Treatment with ApoC3 siRNA attenuated plasma Abeta42 and modestly reduced neurovascular inflammation. Conclusion The findings further support the hypothesis that aberrant peripheral metabolism of lipoprotein-Abeta is associated with microvascular corruption and the development of anxiety-like behaviour. HA1 is more effective than probucol or ApoC3 siRNA in positively modulating lipoprotein-amyloid homeostasis in db/db mice and maintaining central capillary integrity.

Altering plasma lipids and liver enzyme activities via hippocampal injections of hen Lysozyme amyloid aggregates in an Alzheimer's disease mouse model: Insights into the therapeutic role of Bis (Indolyl) phenylmethane

Effects of BIS-MEP on Reversing Amyloid Plaque Deposition and Spatial Learning and Memory Impairments in a Mouse Model of Β-Amyloid Peptide- and Ibotenic Acid-Induced Alzheimer’s Disease

β-Sheet Breaker Peptide-HPYD for the Treatment of Alzheimer's Disease: Primary Studies on Behavioral Test and Transcriptional Profiling

Tetradecyl 2,3-Dihydroxybenzoate Improves Cognitive Function in AD Mice by Modulating Autophagy and Inflammation Through IPA and Hsc70 Targeting

Preformulation Studies of a Stable PTEN-PDZ Lipopeptide Able to Cross an In Vitro Blood-Brain-Barrier Model as a Potential Therapy for Alzheimer's Disease

Self-assembling nanofibers alter the processing of amyloid precursor protein in a transgenic mouse model of Alzheimer's disease.

12/15-LIPOXYGENASE INHIBITION REVERSES COGNITIVE IMPAIRMENT, AMYLOIDOSIS, TAU AND SYNAPTIC PATHOLOGY BY STIMULATING AUTOPHAGY IN THE BRAIN OF AGED 3XTG MICE

Effects of HA1 (a Probucol Analogue) and ApoC3 siRNA on Lipoprotein-Amyloid Metabolism, Neurovascular Integrity and Cognitive Function in db/db Mice

Lipid-polymer hybrid nanoparticles loaded with N-acetylcysteine for the modulation of neuroinflammatory biomarkers in Human iPSC-Derived PSEN2 (N141I) Astrocytes as a model of Alzheimer's Disease

A Novel Peroxidase Mimics And Ameliorates Alzheimer'S Disease-Related Pathology And Cognitive Decline In Mice

Therapeutic Efficacy of Plasmalogens for Alzheimer's Disease, Mild Cognitive Impairment, and Parkinson's Disease in Conjunction with a New Hypothesis for the Etiology of Alzheimer's Disease

Aβ1-42 peptide toxicity on neuronal cells: A lipidomic study

Investigation of Plasma Metabolomics and Neurotransmitter Dysfunction in the Process of Alzheimer's Disease Rat Induced by Amyloid Beta 25-35

Therapeutic treatment with the anti-inflammatory drug candidate MW151 may partially reduce memory impairment and normalizes hippocampal metabolic markers in a mouse model of comorbid amyloid and vascular pathology

Lipidomic analysis of brain tissues and plasma in a mouse model expressing mutated human amyloid precursor protein/tau for Alzheimer’s disease

P1‐017: 12/15‐lipoxygenase Inhibition Reverses Cognitive Impairment, Amyloidosis, TAU and Synaptic Pathology by Stimulating Autophagy in the Brain of Aged 3XTG Mice

Liver Bile Acid Changes in Mouse Models of Alzheimer’s Disease

An In Vitro and In Vivo Investigation

Treatment with 1, 10 Phenanthroline-5-Amine Reduced Amyloid Burden in a Mouse Model of Alzheimer's Disease

Lipoprotein-Based Nanoparticles Rescue the Memory Loss of Mice with Alzheimer'S Disease by Accelerating the Clearance of Amyloid-Beta

Prominent Effects of Berbamine Hydrochloride on Alzheimer's Disease Model Mice.